Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Accured Expenses (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Change in Accured Expenses data on record, last reported at -$9.2 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 470.79% year-over-year to -$9.2 million; the TTM value through Sep 2025 reached -$59.4 million, down 219.56%, while the annual FY2024 figure was -$33.3 million, 168.92% down from the prior year.
  • Change in Accured Expenses reached -$9.2 million in Q3 2025 per PTCT's latest filing, up from -$35.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $50.1 million in Q4 2023 and bottomed at -$35.8 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is -$1.2 million, with a median of -$1.2 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: soared 1952.61% in 2022, then tumbled 1534.6% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$15.6 million in 2021, then surged by 60.71% to -$6.1 million in 2022, then soared by 917.86% to $50.1 million in 2023, then plummeted by 165.68% to -$32.9 million in 2024, then soared by 72.11% to -$9.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$9.2 million in Q3 2025, -$35.8 million in Q2 2025, and $18.5 million in Q1 2025.